Chondrex: New marker of joint disease

Clinical Chemistry

Volumn 44, Issue 3, 1998, Pages 509-516

  Harvey, Sheryl ^a   Weisman, Michael ^b   O'Dell, James ^c   Scott, Tonya ^a   Krusemeier, Mindy ^a   Visor, Jill ^d   Swindlehurst, Cathy ^a  

^a Novadex Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d Quidel Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHONDREX; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PROTEIN DETERMINATION; RHEUMATOID ARTHRITIS;

EID: 0031911418     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/44.3.509     Document Type: Article

References (14)

1. Rejman JJ, Hurley WL. Isolation and characterization of a novel 39 kilodalton whey protein from bovine mammary secretions collected during the nonlactating period. Biochem Biophys Res Commun 1988;150:329-34.
2. Johansen JS, Williamson MK, Rice JS, Price PA. Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 1992;7:501-12.
3. Johansen JS, Jensen HS, Price PA. A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br J Rheumatol 1993;32:949-55.
4. Hakala BE, White C. Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993;268:25803-10.
5. Nyirkos P, Golds EE. Human synovial cells secrete a 39 kDa protein similar to a bovine mammary protein expressed during the non-lactating period. Biochem J 1990;268:265-8.
6. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA. Serum YKL-40 levels on healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996; 35:553-9.
7. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
8. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine [Review]. CNn Chem 1993;39:561-77.
9. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42:558-63.
10. Burger H, van Daele PL, Odding E, Valkenberg HA, Hofman A, Grobbee DE, et al. Association of radiographically evident osteoarthritis with higher bone mineral density and increased bone loss with age. The Rotterdam study. Arthritis Rheum 1996;39:81-6.
11. Johansen JS, Hansen M, Stoltenberg M, Hvolris J, Florescu A, Price PA, Hørslev-Petersen K. Does serum YKL-40 reflect disease activity in rheumatoid arthritis and osteoarthritis? [Abstract]. Arthritis Rheum 1995;38(9, Suppl):S217.
12. Verheijden GFM, Rijnders AWM, Bos E, Coenen-de Roo CJJ, van Stavern CJ, Miltenburg AMM, et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Rheum 1997;40:1115-25.
13. Volck B, Johansen JS, Stoltenberg M, Østergaard M, Price PA, Lorenzen I. Serum YKL-40 reflects pharmacological induced reduction of synovial inflammation of the knee joint in patients with rheumatoid arthritis [Abstract]. Arthritis Rheum 1996;39: S155.
14. Johansen JS, Stoltenberg M, Hansen M, Hansen TM, Price PA, Getzche PC. Serum YKL-40 reflects disease relapse after withdrawal of SAARD in patients with rheumatoid arthritis [Abstract]. Arthritis Rheum 1996;39:S155.